Unigene and China's SPG extend deal
US biopharmaceutcal company Unigene Laboratories has announced plans to broaden the scope of its joint venture with China's Shijiazhuang Pharmaceutical. The New Jersey-headquartered firm said that it would establish the SPG-Unigene Biotechnology Research Institute in China to continue the local registration of its range of calcitonin products. The firm added that the new facility will incorporate manufacturing operations that are compliant with US Good Manufacturing Practice guidelines, and would serve as the hub of a new distribution network. Unigene will maintain both its 45% holding in the joint venture as well as its previously-agreed $15.0 million investment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze